These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 26927985)

  • 21. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China.
    Shang P; Xia Y; Liu F; Wang X; Yuan Y; Hu D; Tu D; Chen Y; Deng P; Cheng S; Zhou L; Ma Y; Zhu L; Gao W; Wang H; Chen D; Yang L; He P; Wu S; Tang S; Lv X; Shu Z; Zhang Y; Yang Z; Chen Y; Li N; Sun F; Li X; He Y; Garner P; Zhan S
    PLoS One; 2011; 6(7):e21836. PubMed ID: 21750735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of hepatotoxicity among patients treated with antituberculous medication.
    Cusack RP; Chawke L; O'Brien DJ; O'Connor B; O'Connor TM
    QJM; 2017 Apr; 110(4):219-225. PubMed ID: 27667826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis.
    Saito Z; Kaneko Y; Kinoshita A; Kurita Y; Odashima K; Horikiri T; Yoshii Y; Seki A; Seki Y; Takeda H; Kuwano K
    BMC Infect Dis; 2016 Nov; 16(1):668. PubMed ID: 27835982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury.
    Devarbhavi H; Singh R; Patil M; Sheth K; Adarsh CK; Balaraju G
    J Gastroenterol Hepatol; 2013 Jan; 28(1):161-7. PubMed ID: 23020522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis.
    Liu YM; Cheng YJ; Li YL; Liu CE; Hsu WH
    Lung; 2014 Feb; 192(1):205-10. PubMed ID: 24292367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors.
    Shakya R; Rao BS; Shrestha B
    Ann Pharmacother; 2004 Jun; 38(6):1074-9. PubMed ID: 15122004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors.
    Bouazzi OE; Hammi S; Bourkadi JE; Tebaa A; Tanani DS; Soulaymani-Bencheikh R; Badrane N; Bengueddour R
    Pan Afr Med J; 2016; 25():167. PubMed ID: 28292129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment.
    Sharma SK; Balamurugan A; Saha PK; Pandey RM; Mehra NK
    Am J Respir Crit Care Med; 2002 Oct; 166(7):916-9. PubMed ID: 12359646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managing Hepatotoxicity Caused by Anti-tuberculosis Drugs: A Comparative Study of Approaches.
    Abbaspour F; Hasannezhad M; Khalili H; SeyedAlinaghi S; Jafari S
    Arch Iran Med; 2024 Mar; 27(3):122-126. PubMed ID: 38685836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic polymorphisms of CYP2E1 and GSTM1 loci and susceptibility to anti-tuberculosis drug-induced hepatotoxicity.
    Sharma SK; Jha BK; Sharma A; Sreenivas V; Upadhyay V; Jaisinghani C; Singla R; Mishra HK; Soneja M
    Int J Tuberc Lung Dis; 2014 May; 18(5):588-93. PubMed ID: 24903797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity.
    Fernández-Villar A; Sopeña B; Fernández-Villar J; Vázquez-Gallardo R; Ulloa F; Leiro V; Mosteiro M; Piñeiro L
    Int J Tuberc Lung Dis; 2004 Dec; 8(12):1499-505. PubMed ID: 15636498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity.
    Satyaraddi A; Velpandian T; Sharma SK; Vishnubhatla S; Sharma A; Sirohiwal A; Makharia GK; Sinha S; Biswas A; Singh S
    Int J Tuberc Lung Dis; 2014 Feb; 18(2):188-95, i-iii. PubMed ID: 24429311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
    Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
    Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic polymorphisms of N-acetyltransferase 2 & susceptibility to antituberculosis drug-induced hepatotoxicity.
    Sharma SK; Jha BK; Sharma A; Sreenivas V; Upadhyay V; Jaisinghani C; Singla R; Mishra HK; Soneja M
    Indian J Med Res; 2016 Dec; 144(6):924-928. PubMed ID: 28474630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study.
    Song JH; Yoon SY; Park TY; Heo EY; Kim DK; Chung HS; Lee JK
    Respir Res; 2019 Dec; 20(1):283. PubMed ID: 31842883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alanine transaminase and hemoglobin appear to predict the occurrence of antituberculosis medication hepatotoxicity; findings and implications in Botswana.
    Kesenogile B; Godman B; Rwegerera GM
    Expert Rev Anti Infect Ther; 2021 Mar; 19(3):379-391. PubMed ID: 32909487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection.
    Wong WM; Wu PC; Yuen MF; Cheng CC; Yew WW; Wong PC; Tam CM; Leung CC; Lai CL
    Hepatology; 2000 Jan; 31(1):201-6. PubMed ID: 10613746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antituberculosis drug-induced hepatotoxicity: a comparison between patients with and without human immunodeficiency virus seropositivity.
    Coca NS; Oliveira MS; Voieta I; Antunes CM; Lambertucci JR
    Rev Soc Bras Med Trop; 2010; 43(6):624-8. PubMed ID: 21181011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia.
    Marzuki OA; Fauzi AR; Ayoub S; Kamarul Imran M
    Singapore Med J; 2008 Sep; 49(9):688-93. PubMed ID: 18830542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of cigarette smoking and liver enzymes polymorphisms in anti-tuberculosis drug-induced hepatotoxicity in Brazilian patients.
    Zaverucha-do-Valle C; Monteiro SP; El-Jaick KB; Rosadas LA; Costa MJ; Quintana MS; de Castro L
    Tuberculosis (Edinb); 2014 May; 94(3):299-305. PubMed ID: 24793319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.